Cargando…
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
Early experience in MS generated concerns that interferon beta treatment might provoke onset or worsening of depression. The objective of the study was to compare depression incidence in relapsing–remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND t...
Autores principales: | Schippling, Sven, O’Connor, Paul, Knappertz, Volker, Pohl, Christoph, Bogumil, Timon, Suarez, Gustavo, Cook, Stuart, Filippi, Massimo, Hartung, Hans-Peter, Comi, Giancarlo, Jeffery, Douglas R., Kappos, Ludwig, Goodin, Douglas S., Arnason, Barry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929160/ https://www.ncbi.nlm.nih.gov/pubmed/27177997 http://dx.doi.org/10.1007/s00415-016-8146-8 |
Ejemplares similares
-
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015) -
Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung, Hans-Peter, et al.
Publicado: (2012) -
Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS
por: Goodin, Douglas S., et al.
Publicado: (2011) -
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
por: Goodin, Douglas S., et al.
Publicado: (2014) -
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
por: Goodin, Douglas S, et al.
Publicado: (2012)